Osteoprotegerin and Denosumab Stimulate Human Beta Cell Proliferation through Inhibition of the Receptor Activator of NF-κB Ligand Pathway

Cell Metabolism

Volumn 22, Issue 1, 2015, Pages 77-85

  Kondegowda, Nagesha Guthalu ^a   Fenutria, Rafael ^a   Pollack, Ilana R ^a   Orthofer, Michael ^b   Garcia Ocaña, Adolfo ^a   Penninger, Josef M ^b   Vasavada, Rupangi C ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DENOSUMAB; GLUCOSE; GLYCOGEN SYNTHASE KINASE 3; INSULIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PROLACTIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; RECOMBINANT CYTOKINE; BONE DENSITY CONSERVATION AGENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DEDIFFERENTIATION; CELL DIVISION; CELL FUNCTION; CELL LOSS; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; GENE DELETION; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE TEST; HOMEOSTASIS; HUMAN; HUMAN CELL; HYPERGLYCEMIA; IN VITRO STUDY; IN VIVO STUDY; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSTEOPOROSIS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL LINE; CYTOLOGY; DIABETES MELLITUS, EXPERIMENTAL; DRUG EFFECTS; METABOLISM; RAT; SCID MOUSE; SIGNAL TRANSDUCTION;

MUS; RODENTIA;

ANIMALS; BONE DENSITY CONSERVATION AGENTS; CELL LINE; CELL PROLIFERATION; DENOSUMAB; DIABETES MELLITUS, EXPERIMENTAL; HUMANS; INSULIN-SECRETING CELLS; MALE; MICE; MICE, INBRED C57BL; MICE, SCID; NF-KAPPA B; OSTEOPROTEGERIN; RANK LIGAND; RATS; SIGNAL TRANSDUCTION;

EID: 84937420517     PISSN: 15504131     EISSN: 19327420     Source Type: Journal    
DOI: 10.1016/j.cmet.2015.05.021     Document Type: Article

References (42)

1. G.M. Beattie, P. Itkin-Ansari, V. Cirulli, G. Leibowitz, A.D. Lopez, S. Bossie, M.I. Mally, F. Levine, and A. Hayek Sustained proliferation of PDX-1+ cells derived from human islets Diabetes 48 1999 1013 1019
2. Y. Dor, J. Brown, O.I. Martinez, and D.A. Melton Adult pancreatic beta-cells are formed by self-duplication rather than stem-cell differentiation Nature 429 2004 41 46
3. M. Freemark, I. Avril, D. Fleenor, P. Driscoll, A. Petro, E. Opara, W. Kendall, J. Oden, S. Bridges, N. Binart, and et al. Targeted deletion of the PRL receptor: effects on islet development, insulin production, and glucose tolerance Endocrinology 143 2002 1378 1385
4. Y. Fujinaka, D. Sipula, A. Garcia-Ocaña, and R.C. Vasavada Characterization of mice doubly transgenic for parathyroid hormone-related protein and murine placental lactogen: a novel role for placental lactogen in pancreatic beta-cell survival Diabetes 53 2004 3120 3130
5. Y. Fujinaka, K. Takane, H. Yamashita, and R.C. Vasavada Lactogens promote beta cell survival through JAK2/STAT5 activation and Bcl-XL upregulation J. Biol. Chem. 282 2007 30707 30717
6. N.K. Guthalu, X.Y. Zhang, K. Williams, A. Mozar, and R.C. Vasavada Growth factor mediated regulation of beta cell survival Open Endocrine J. 4 2010 80 95
7. R. Hanada, T. Hanada, and J.M. Penninger Physiology and pathophysiology of the RANKL/RANK system Biol. Chem. 391 2010 1365 1370
8. J.S. Hong, J. Santolaya-Forgas, R. Romero, J. Espinoza, L.F. Gonçalves, Y.M. Kim, S. Edwin, B.H. Yoon, J.K. Nien, S. Hassan, and M. Mazor Maternal plasma osteoprotegerin concentration in normal pregnancy Am. J. Obstet. Gynecol. 193 2005 1011 1015
9. C. Huang, F. Snider, and J.C. Cross Prolactin receptor is required for normal glucose homeostasis and modulation of beta-cell mass during pregnancy Endocrinology 150 2009 1618 1626
10. M.A. Hussain, D.L. Porras, M.H. Rowe, J.R. West, W.J. Song, W.E. Schreiber, and F.E. Wondisford Increased pancreatic beta-cell proliferation mediated by CREB binding protein gene activation Mol. Cell. Biol. 26 2006 7747 7759
11. M.L. Isidro, and B. Ruano Bone disease in diabetes Curr. Diabetes Rev. 6 2010 144 155
12. A.E. Kearns, S. Khosla, and P.J. Kostenuik Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease Endocr. Rev. 29 2008 155 192
13. S. Kiechl, J. Wittmann, A. Giaccari, M. Knoflach, P. Willeit, A. Bozec, A.R. Moschen, G. Muscogiuri, G.P. Sorice, T. Kireva, and et al. Blockade of receptor activator of nuclear factor-κB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus Nat. Med. 19 2013 358 363
14. N.G. Kondegowda, A. Mozar, C. Chin, A. Otero, A. Garcia-Ocaña, and R.C. Vasavada Lactogens protect rodent and human beta cells against glucolipotoxicity-induced cell death through Janus kinase-2 (JAK2)/signal transducer and activator of transcription-5 (STAT5) signalling Diabetologia 55 2012 1721 1732
15. P.J. Kostenuik, H.Q. Nguyen, J. McCabe, K.S. Warmington, C. Kurahara, N. Sun, C. Chen, L. Li, R.C. Cattley, G. Van, and et al. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL J. Bone Miner. Res. 24 2009 182 195
16. R.N. Kulkarni, E.B. Mizrachi, A.G. Ocana, and A.F. Stewart Human β-cell proliferation and intracellular signaling: driving in the dark without a road map Diabetes 61 2012 2205 2213
17. B. Kutlu, D. Burdick, D. Baxter, J. Rasschaert, D. Flamez, D.L. Eizirik, N. Welsh, N. Goodman, and L. Hood Detailed transcriptome atlas of the pancreatic beta cell BMC Med. Genomics 2 2009 3
18. E.H. Leiter Multiple low-dose streptozotocin-induced hyperglycemia and insulitis in C57BL mice: influence of inbred background, sex, and thymus Proc. Natl. Acad. Sci. USA 79 1982 630 634
19. H. Liu, M.S. Remedi, K.L. Pappan, G. Kwon, N. Rohatgi, C.A. Marshall, and M.L. McDaniel Glycogen synthase kinase-3 and mammalian target of rapamycin pathways contribute to DNA synthesis, cell cycle progression, and proliferation in human islets Diabetes 58 2009 663 672
20. P.D. Miller Denosumab: anti-RANKL antibody Curr. Osteoporos. Rep. 7 2009 18 22
21. S. Mochizuki, N. Fujise, K. Higashio, and E. Tsuda Osteoclastogenesis inhibitory factor/osteoprotegerin ameliorates the decrease in both bone mineral density and bone strength in immobilized rats J. Bone Miner. Metab. 20 2002 14 20
22. M.S. Ominsky, M. Stolina, X. Li, T.J. Corbin, F.J. Asuncion, M. Barrero, Q.T. Niu, D. Dwyer, S. Adamu, K.S. Warmington, and et al. One year of transgenic overexpression of osteoprotegerin in rats suppressed bone resorption and increased vertebral bone volume, density, and strength J. Bone Miner. Res. 24 2009 1234 1246
23. R.A. Oram, A.G. Jones, R.E. Besser, B.A. Knight, B.M. Shields, R.J. Brown, A.T. Hattersley, and T.J. McDonald The majority of patients with long-duration type 1 diabetes are insulin microsecretors and have functioning beta cells Diabetologia 57 2014 187 191
24. L.E. Padgett, K.A. Broniowska, P.A. Hansen, J.A. Corbett, and H.M. Tse The role of reactive oxygen species and proinflammatory cytokines in type 1 diabetes pathogenesis Ann. N Y Acad. Sci. 1281 2013 16 35
25. G. Parnaud, D. Bosco, T. Berney, F. Pattou, J. Kerr-Conte, M.Y. Donath, C. Bruun, T. Mandrup-Poulsen, N. Billestrup, and P.A. Halban Proliferation of sorted human and rat beta cells Diabetologia 51 2008 91 100
26. S. Perl, J.A. Kushner, B.A. Buchholz, A.K. Meeker, G.M. Stein, M. Hsieh, M. Kirby, S. Pechhold, E.H. Liu, D.M. Harlan, and J.F. Tisdale Significant human beta-cell turnover is limited to the first three decades of life as determined by in vivo thymidine analog incorporation and radiocarbon dating J. Clin. Endocrinol. Metab. 95 2010 E234 E239
27. P. Rao, J. Roccisana, K.K. Takane, R. Bottino, A. Zhao, M. Trucco, and A. García-Ocaña Gene transfer of constitutively active Akt markedly improves human islet transplant outcomes in diabetic severe combined immunodeficient mice Diabetes 54 2005 1664 1675
28. S. Rieck, and K.H. Kaestner Expansion of beta-cell mass in response to pregnancy Trends Endocrinol. Metab. 21 2010 151 158
29. S. Rieck, P. White, J. Schug, A.J. Fox, O. Smirnova, N. Gao, R.K. Gupta, Z.V. Wang, P.E. Scherer, M.P. Keller, and et al. The transcriptional response of the islet to pregnancy in mice Mol. Endocrinol. 23 2009 1702 1712
30. M.M. Sachdeva, and D.A. Stoffers Minireview: Meeting the demand for insulin: molecular mechanisms of adaptive postnatal beta-cell mass expansion Mol. Endocrinol. 23 2009 747 758
31. M. Saito, Y. Kida, S. Kato, and K. Marumo Diabetes, collagen, and bone quality Curr. Osteoporos. Rep. 12 2014 181 188
32. J. Schrader, W. Rennekamp, U. Niebergall, M. Schoppet, H. Jahr, M.D. Brendel, D. Hörsch, and L.C. Hofbauer Cytokine-induced osteoprotegerin expression protects pancreatic beta cells through p38 mitogen-activated protein kinase signalling against cell death Diabetologia 50 2007 1243 1247
33. A.V. Schwartz, A.L. Schafer, A. Grey, E. Vittinghoff, L. Palermo, L.Y. Lui, R.B. Wallace, S.R. Cummings, D.M. Black, D.C. Bauer, and I.R. Reid Effects of antiresorptive therapies on glucose metabolism: results from the FIT, HORIZON-PFT, and FREEDOM trials J. Bone Miner. Res. 28 2013 1348 1354
34. W.S. Simonet, D.L. Lacey, C.R. Dunstan, M. Kelley, M.S. Chang, R. Lüthy, H.Q. Nguyen, S. Wooden, L. Bennett, T. Boone, and et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density Cell 89 1997 309 319
35. M. Teta, S.Y. Long, L.M. Wartschow, M.M. Rankin, and J.A. Kushner Very slow turnover of beta-cells in aged adult mice Diabetes 54 2005 2557 2567
36. B. Toffoli, S. Bernardi, R. Candido, N. Sabato, R. Carretta, F. Corallini, P. Secchiero, G. Zauli, and B. Fabris Osteoprotegerin induces morphological and functional alterations in mouse pancreatic islets Mol. Cell. Endocrinol. 331 2011 136 142
37. R.C. Vasavada, A. Garcia-Ocaña, W.S. Zawalich, R.L. Sorenson, P. Dann, M. Syed, L. Ogren, F. Talamantes, and A.F. Stewart Targeted expression of placental lactogen in the beta cells of transgenic mice results in beta cell proliferation, islet mass augmentation, and hypoglycemia J. Biol. Chem. 275 2000 15399 15406
38. R.C. Vasavada, J.A. Gonzalez-Pertusa, Y. Fujinaka, N.M. Fiaschi-Taesch, I. Cozar, and A. Garcia-Ocaña Growth factors and pancreatic beta cell proliferation International J. Cell Biol. Biochem. 38 2006 931 950
39. R.C. Vasavada, L. Wang, Y. Fujinaka, K.K. Takane, T.C. Rosa, J.M. Mellado-Gil, P.A. Friedman, and A. Garcia-Ocaña Protein kinase C-zeta activation markedly enhances beta-cell proliferation: an essential role in growth factor mediated beta-cell mitogenesis Diabetes 56 2007 2732 2743
40. S. Vitovski, J.S. Phillips, J. Sayers, and P.I. Croucher Investigating the interaction between osteoprotegerin and receptor activator of NF-kappaB or tumor necrosis factor-related apoptosis-inducing ligand: evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways J. Biol. Chem. 282 2007 31601 31609
41. G.C. Weir, and S. Bonner-Weir Islet β cell mass in diabetes and how it relates to function, birth, and death Ann. N Y Acad. Sci. 1281 2013 92 105
42. K. Williams, D. Abanquah, S. Joshi-Gokhale, A. Otero, H. Lin, N.K. Guthalu, X. Zhang, A. Mozar, A. Bisello, A.F. Stewart, and et al. Systemic and acute administration of parathyroid hormone-related peptide(1-36) stimulates endogenous beta cell proliferation while preserving function in adult mice Diabetologia 54 2011 2867 2877